New Phase 2a trial registered for Amgen's xaluritamig after lutetium-177 therapy
Thomas Jefferson University registered a phase 2a study testing Amgen's xaluritamig in prostate cancer patients with limited response to prior radioligand therapy.
A single new trial registration this period involves Amgen as a collaborator on an academically sponsored study.
- "LuX" is a phase 2a, single-arm study of xaluritamig in metastatic castrate-resistant prostate cancer, sponsored by Thomas Jefferson University with Amgen as a collaborator. The study is designed for mCRPC patients following treatment with at least one ARPI, taxane chemotherapy if eligible, and stable or partial PSA response following 2 cycles of lutetium 177 vipivotide tetraxetan.1 Status is not yet recruiting, with an estimated enrollment of approximately 30 participants.1 The primary endpoint is a composite measure of response, defined as a confirmed Complete Response or Partial Response within 24 weeks by local investigator assessment per RECIST v1.1, or a confirmed PSA90 response, defined as a decline of at least 90% from baseline PSA in participants with baseline PSA of at least 2.0 ng/mL within 24 weeks.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.